Overview

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)

Status:
Not yet recruiting

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Tislelizumab plus Lenvatinib for patients with gastric cancer liver metastasis in the second-/third-Line setting.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Lenvatinib
Tislelizumab